// App-Quantinova.ai

2287 : Final results of the pharmacodynamic (PD) data of PQR309-001, a first-in-human trial of a combined PI3K/mTOR inhibitor in advanced solid tumors

Researchers

Presenter

  • Andreas Wicki

Principal Investigators

  • Vincent Pretre

  • Reto Ritschard

  • Nicholas Brown

  • Vincent Bize

  • Thomas Fabbro

  • Natasa Cmiljanovic

  • Sasa Dimitrijevic

  • Deborah Schmitz

  • Michael Stumm

  • Rebecca Kristeleit

Medical Centers

  • University Hospital Basel, Basel, Switzerland

  • Kings College London, London, United Kingdom

  • Swiss Group for Clinical Cancer Research SAKK, Berne, Switzerland

  • Piqur Therapeutics AG, Basel, Switzerland

  • University College London Hospitals/UCL Cancer Institute, London, United Kingdom

Locations

  • Switzerland

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

  • Serine/threonine-protein kinase mTOR

Drug/Treatment

  • PQR309

Outcome

  • N/A

Study Design

  • Pharmacodynamics

  • Dose Escalation

  • First-In-Human

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved